This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Andy Yeung, Ph.D.
Chief Technology Officer at Asher Biotherapeutics


Andy Yeung currently serves as the Chief Technology Officer of Asher Biotherapeutics, responsible for the engineering and development of antibody and cytokine candidates. Previously Andy was at Pfizer, leading protein engineering efforts for various programs including CD3 bispecific, CAR T, and immuno-oncology (antibodies and cytokines). Prior to Pfizer, Andy was a post-doctoral fellow in the Antibody Engineering Department at Genentech. Andy received his Ph.D. and M.S. in Chemical engineering from Massachusetts Institute of Technology, and a B.Sc. in Chemical Engineering from University of Wisconsin-Madison.

Agenda Sessions

  • Engineering Cis-Targeted Immunomodulators to Enhance Their Selectivity and Effectiveness as Therapeutics